What Happened?
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiring rights to a preclinical Alzheimer's drug and entering a collaboration for an ion channel program.
According to a company press release, Eli Lilly acquired global rights to AlzeCure Pharma's Alzheimer's drug candidate, ACD680, for an upfront payment of $10 million. In addition, the agreement could exceed $1 billion in total value through future development and commercial milestone payments, plus mid-single-digit royalties on sale. ACD680 is expected to sit upstream of Kisunla, Lilly’s marketed amyloid antibody, which the company said generated $167 million in the second quarter.
In a separate agreement, Eli Lilly entered into a global collaboration with OmniAb for a new ion channel program, PharmExec reported. Under that deal, OmniAb will receive an upfront payment and is eligible for up to $370 million in milestone payments, along with tiered royalties on global net sales.
These low-upfront, milestone-driven agreements should enable Lilly to continuously reload its early-stage pipeline with high-upside assets while fully protecting its near-term margins. More strategically, securing upstream candidates like ACD680 helps the company to build a fortified, multi-mechanism moat around its nascent Alzheimer's franchise, ensuring it retains market leadership as the standard of care inevitably evolves beyond initial amyloid clearance.
The shares closed the day at $1,227, up 3.6% from the previous close.
Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Eli Lilly’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 13 days ago when the stock gained 2.5% on the news that the company delivered a massive "beat and raise" in its second-quarter report, driven by insatiable demand for its blockbuster GLP-1 weight-loss and diabetes drugs.
The company posted explosive top-line growth, with revenue jumping 47.7% year-over-year to $22.97 billion, blowing past analysts' expectations of $20.62 billion (an 11.4% beat). Profitability was equally impressive, as adjusted earnings of $8.38 per share crushed consensus estimates by 27.3%. The phenomenal performance was largely attributed to surging sales of Mounjaro and Zepbound, proving that Eli Lilly continues to capitalize on the massive total addressable market for obesity treatments.
Buoyed by the momentum, management confidently raised its full-year outlook. The company increased its 2026 revenue guidance by 3% to a midpoint of $86 billion (up from $83.5 billion). It also lifted its full-year adjusted EPS guidance by 5.8% to $36.25 at the midpoint.
Notably, management highlighted that they actually raised their underlying EPS forecast by $2.78 per share, though this was offset by $3.03 per share in charges tied to deals executed during the quarter. While operating margins did compress to 39.1% (down from 44.1% a year ago), investors eagerly looked past it, focusing instead on the relentless sales growth that has pushed Eli Lilly's market capitalization to the brink of $1 trillion.
Eli Lilly is up 13.4% since the beginning of the year, and at $1,225 per share, it is trading close to its 52-week high of $1,236 from July 2026. Investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $4,563.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.